MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine  by Medini, Duccio et al.
RM
m
D
a
b
a
A
R
R
A
A
K
M
4
M
M
M
1
c
i
p
t
[
i
o
a
t
d
u
f
h
0
0Vaccine 33 (2015) 2629–2636
Contents lists available at ScienceDirect
Vaccine
j our na l ho me page: www.elsev ier .com/ locate /vacc ine
eview
ATS:  Global  coverage  estimates  for  4CMenB,  a  novel
ulticomponent  meningococcal  B  vaccine
uccio  Medinia,∗, Maria  Stellaa,  James  Wassilb
GSK Vaccines, Siena, Italy
GSK Vaccines, Cambridge, MA,  USA
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 16 October 2014
eceived in revised form 31 March 2015
ccepted 3 April 2015
vailable online 13 April 2015
eywords:
eningococcal B vaccine
CMenB
eningococcal Antigen Typing System
ATS
eningitis
a  b  s  t  r  a  c  t
Recently  approved  in  the EU,  US,  Australia,  and  Canada,  4CMenB  (Bexsero®, GSK Vaccines)  is  a  multi-
component  meningococcal  B (MenB)  vaccine  containing  3 surface  exposed  recombinant  proteins  (fHbp,
NadA,  and  NHBA)  and  New  Zealand  strain  outer  membrane  vesicles  (NZ  OMV)  containing  PorA  1.4.  The
accepted  correlate  of protection  to assess  response  to MenB  vaccines,  the  serum  bactericidal  assay  with
human  complement,  is  impractical  for  large  panels  of  strains  with  diverse  antigenic  proﬁle  and  expres-
sion.  Therefore,  the Meningococcal  Antigen  Typing  System  (MATS)  was  developed  to  identify  MenB
strains  with  a  high  likelihood  of  being  covered  by 4CMenB.  MATS  is used  to  assess  MenB  strain  cov-
erage  without  requiring  sera,  an advantage  for  testing  large  panels  of  bacterial  isolates.  MATS  provides
an  accurate,  conservative  estimate  of  4CMenB  coverage.  In a  public–private  partnership,  10  reference
laboratories  around  the  world  were  established  and  standardized  to facilitate  the  timely  collection  and
analysis  of regional  data. MATS  has  global  public  health  implications  for informing  local  policy  makers  of
the predicted  effect  of  the  implementation  of  the  4CMenB  vaccine.  Coverage  estimates  are  similar  to or
better than  other  recently  approved  vaccines,  ranging  from  66%  to  91%.  The  use of MATS  in  post-vaccine
implementation  surveillance  could  provide  data  regarding  vaccine  effectiveness  in  the ﬁeld  and  duration
of protection  on a global  scale  that  will  aid  in  the  development  of  vaccine  booster  schedules,  if neces-
sary.  This MATS  approach  could  potentially  be applied  rapidly  to  assess  epidemiology  of  other  bacterial
pathogens  and  coverage  by other  protein-based  vaccines.
©  2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
Globally, Neisseria meningitidis causes an estimated 500,000
ases of invasive meningococcal disease (IMD) per year, approx-
mately 50,000 of which result in death. Survivors often sustain
ermanent and debilitating sequelae [1]. Serogroup B N. meningi-
idis (MenB) is now the leading cause of IMD  in developed countries
2,3].
Development of a MenB vaccine was complicated by the lack of
mmunogenicity of the polysaccharide capsule, the potential risks
f autoantibodies that cross-react with glycosylated host antigens
nd the high level of genetic and antigenic diversity exhibited by
he meningococcus [4,5]. Decades of biomedical research have been
edicated to the development of vaccines against MenB disease,
sing either wild-type outer membrane vesicles (OMVs) [6,7] or
∗ Corresponding author at: Via Fiorentina 1, Siena, Italy. Tel.: +39 0577 243063;
ax:  +39 0577 243564.
E-mail address: duccio.x.medini@gsk.com (D. Medini).
ttp://dx.doi.org/10.1016/j.vaccine.2015.04.015
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article 
/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
sub-capsular protein targets [8–12]. Although OMV-based vaccines
have been used to control local outbreaks, they fail to provide broad
protection against heterologous endemic MenB strains [8,9,11–16].
Reverse vaccinology, a new genomic-based approach for the
design of vaccines, was  used to identify a number of protein tar-
gets that could help prevent IMD  caused by any capsular serogroup
[17–19]. These novel components included Neisserial adhesin A
(NadA), Neisseria heparin-binding antigen (NHBA) and factor H-
binding protein (fHbp) in combination with New Zealand strain
outer membrane vesicles (NZ OMV) with PorA 1.4. The resulting
vaccine, 4CMenB (Bexsero®, GSK Vaccines) was the ﬁrst broad-
coverage MenB vaccine based on recombinant proteins and was
approved for use in individuals 2 months of age and above by the
European Commission in January 2013, and was recently approved
for use in individuals from 10 to 25 years of age by the FDA in
January 2015 [20,21]. 4CMenB has also been approved in Australia,
Canada, and Uruguay.
Immunogenicity of meningococcal vaccines has been evaluated
by means of complement-mediated killing of bacteria in the serum
bactericidal antibody assay with human complement (hSBA) since
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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he 1960s [22–25]. However, because protein antigens may vary
n their sequence and level of expression, evaluating the effec-
iveness of protein-based vaccines such as 4CMenB would require
esting many different meningococcal strains directly in hSBA –
n impractical undertaking especially for infants, whose serum
olumes are very limited. Due to frequent recombination in the
enB population [5] genotyping-based methods such as multilocus
equence typing [26] are not suitable either. An alternative means
f measuring surface-based antigens was needed and the Meningo-
occal Antigen Typing System (MATS) was developed to meet that
eed. Here, we explain MATS and how it predicts strain killing
y 4CMenB-induced antibodies. We  describe the public–private
ooperation in which the MATS assay platform was  made avail-
ble to meningococcal reference laboratories and the resulting
CMenB coverage estimates in countries around the world. Finally,
e discuss the potential use of MATS for post-implementation
urveillance.
. The Meningococcal Antigen Typing System: MATS
In terms of the standard correlate of protection, vaccine strain
overage can be deﬁned as the proportion of disease-causing
eningococcal isolates killed by immune sera in the hSBA assay,
n a deﬁned region and period of time. Killing in the hSBA of
 bacterial strain depends, for each antigen included in a vac-
ine, mostly on two factors: (i) the amount and (ii) the extent of
mmunologic cross-reactivity of that antigen as expressed on the
acterial surface. Due to the practical impediments to using hSBA
o measure the vaccine strain coverage of a protein-based vac-
ine such as 4CMenB, MATS was developed as a typing system to
nable prediction of the strain coverage for each of the components
n the 4CMenB vaccine. It combines conventional genotyping for
orA (OMV component of 4CMenB) with a specialized sandwich
nzyme-linked immunosorbent assay (MATS–ELISA) to assess the
henotypic expression and cross-reactivity of the other 4CMenB
accine antigens (fHbp, NadA, and NHBA) present on the MenB
urface [26,27].
Conventional genotyping can be used to predict strain cover-
ge for PorA because, unlike most protein antigens, the level of
xpression of PorA, the OMV  component of 4CMenB, shows no
ubstantial variation among circulating strains. For PorA, vaccine
overage is predicted through the PorA VR2 typing (or the equiva-
ent sero-subtype [26]) such that any strain typing P1.4 is predicted
s covered and any other type is not. The MATS–ELISA phenotype
redicts vaccine coverage for the fHbp, NHBA and NadA compo-
ents by deﬁning a relative potency (RP) of the tested strain versus
 reference strain for each antigen (Fig. 1; see Donnelly et al. [28]
or details), and then comparing the RP with a positive bacterici-
al threshold, or PBT. The PBT is the antigen-speciﬁc minimum RP
alue predictive of killing in the hSBA, the accepted correlate of
rotection. If the RP exceeds the PBT for a given antigen, the strain
s predicted as covered by that vaccine antigen. Any strain that is
overed by 1 or more antigen is deﬁned as covered by 4CMenB
MATS-positive).
Note that MATS was designed to measure the speciﬁc four vac-
ine components in 4CMenB (fHbp, NadA, NHBA, and PorA) in terms
f their impact on coverage. MATS was not developed for and can-
ot be used to measure the coverage of the second licensed MenB
accine, rLP2086 (Pﬁzer, Trumenba®). That vaccine is a monocom-
onent vaccine consisting of two fHbp variants and MATS only
ssesses the one fHbp variants (variant 1/subfamily B) that is also
ontained in 4CMenB, but as a different sub-variant. Therefore,
ATS cannot be used to estimate rLP2086 coverage or to compare
he coverage or efﬁcacy of a deﬁned strain panel between 4CMenB
nd rLP2086. (2015) 2629–2636
While the use of PorA typing to predict coverage by the OMV
vaccine component was  already well established, the MATS–ELISA
method needed to be validated against the accepted correlate of
protection. The following section summarizes that validation.
3. MATS predicts strain killing by 4CMenB-induced
antibodies
The MATS–ELISA was designed to predict coverage of fHbp,
NHBA and NadA, in combination with conventional genotyping for
PorA, and was  developed in two  steps [28]. First, sera from subjects
vaccinated with 4CMenB were collected and functional antibodies
to each of a broadly diverse panel of 57 invasive MenB isolates were
measured by traditional hSBA. Pre- and post-vaccination sera were
obtained from randomized clinical trials performed in various age
groups – infants, adolescents and adults. Infants received 4 doses of
4CMenB, while adolescents and adults received either 2 or 3 doses.
To overcome serum limitation and to facilitate testing of large
strain panels, sera were pooled by age group. For each strain, killing
by vaccine-induced antibodies was  deﬁned as a post-vaccination
pooled hSBA titer ≥1:8 and ≥4-times higher than the correspond-
ing pre-vaccination titer. As the largest proportion of killing was
observed with adult and adolescent sera and to ensure that the
MATS estimate would be conservative, infant sera were selected
for the next step of the analysis. Therefore, MATS is considered
conservative, underestimating coverage particularly in older age
groups. Second, MATS–RP was  determined for each antigen against
the 57 strain panel, and these results were compared to killing in
the hSBA using pooled infant sera: an unsupervised algorithm was
used to determine, for each antigen, a minimum RP value predic-
tive of killing in the hSBA. This minimum RP is the antigen-speciﬁc
PBT [28].
Donnelly and colleagues showed that strains that exceeded
the PBT for NadA, NHBA, or fHbp had a probability of ≥82% of
being killed in the hSBA [28]. There was a statistically signiﬁ-
cant association (p < 0.0001) between strains that MATS predicted
would be killed (MATS-positive, i.e., RP > PBT for NadA, NHBA or
fHbp; or PorA type = 1.4) and the correlate of protection data (hSBA
titer ≥1:8 and ≥4-fold pre-vaccination titer), which suggests the
antigen–antibody binding in the MATS–ELISA assay has character-
istics similar to those required for the killing of the bacterium in the
hSBA [28]. Fig. 2 shows that strains with only one MATS-positive
antigen have a high likelihood of being killed in the hSBA. Reinforc-
ing the beneﬁts of a multicomponent vaccine, strains with more
than one MATS-positive antigen have an even higher likelihood of
being killed in the hSBA – strains with 2 MATS-positive antigens
had a 94% (79–99%) probability of being killed in the hSBA whereas
strains with 3 MATS-positive antigens had a 100% (76–100%) prob-
ability of being killed in the hSBA [28].
Sizeable proportions of strains predicted negative by MATS were
indeed killed in hSBA, particularly in older ages (27%, 23%, and 63%
in infants, children and adults, respectively [28]), further demon-
strating the conservativeness of MATS.
Pooled hSBA sera used to validate MATS represent an aver-
age of the seroresponse from individual vaccines. The clinical
relevance of MATS versus individual protection from disease is
further illustrated by an examination of the clinical data accu-
mulated in the 4CMenB program [29–31]. Fig. 3 summarizes the
responses in hSBA from over 7000 infant, adolescent and adult
healthy volunteers against 19 invasive meningococcal strains strat-
iﬁed by MATS (number of antigens predicted MATS-positive). Two
of the 4 strains predicted non-covered by MATS had indeed nega-
tive seroresponse (% individuals above protective threshold < 20%),
whereas 2 had seroresponse ∼80% despite the negative predic-
tion (average seroresponse 46%). Three of the 5 strains predicted
D. Medini et al. / Vaccine 33 (2015) 2629–2636 2631
Fig. 1. MATS process to determine 4CMenB strain coverage. MATS is composed of 3 ELISAs and of PorA genotyping. Test strains (T1–T6) are grown overnight on chocolate
agar  along with Reference strains for each antigen (R-fHbp = strain H44/76; R-NHBA = strain NGH38; R-NadA = strain 5/99). For the ELISA procedure (left panels, for fHbp,
NHBA,  NadA antigens), a suspension of bacteria taken from the plate is prepared to a speciﬁed OD600. Detergent is added to the suspension to extract the capsule and expose
the  antigens. Serial dilutions of extract are tested in the MATS–ELISA. In each assay an antigen-speciﬁc capture antibody (e.g. a-fHbp, blue) binds the antigens from the extract
of  the Test strains (red) and on the reference strain (e.g. R-fHbp, blue), which is then detected with a speciﬁc biotin-labeled antibody and a streptavidin–enzyme conjugate.
Plates are read at 490 nm in an ELISA reader. For each test strain, Relative Potencies (RP) are calculated by comparing the curve of optical densities vs. dilution obtained
with  the serially diluted test strain (red) to the serially diluted reference strain tested in the same ELISA plate (e.g. R-fHbp, blue). Coverage for each antigen is determined
by  comparing each RP with the corresponding Positive Bactericidal Threshold (PBT, see text). For the PorA typing procedure (right panels) bacterial cell cultures for the Test
strains (T1–T6) are boiled, the suspension centrifuged and the supernatant used as source of DNA template for ampliﬁcation. The PorA gene is PCR-ampliﬁed and the PCR
products sequenced using standard primers. VR2 sequences are assigned to variants through the web  site http://neisseria.org/nm/typing/pora/. The coverage is predicted
positive for PorA if and only if the VR2 peptide sequence is matched to the serosubtype P1.4 (VR2 = 4). (For interpretation of the references to color in this ﬁgure legend, the
reader  is referred to the web  version of this article.)
2632 D. Medini et al. / Vaccine 33
Fig. 2. Proportion of strains killed in the hSBA versus the number of MATS-positive
antigens. Strains with one antigen MATS-positive antigen have a high likelihood
of being killed in the hSBA; strains with more than one antigen MATS-positive
antigen have an even higher likelihood of being killed in the hSBA. 1Proportion
of  strains killed in hSBA, deﬁned as number of strains killed/number of strains
tested. 2Number of MATS-positive antigens (predicted by MATS as covered), deﬁned
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ss:  MATS-RP > PBT for NadA, NHBA or fHBP; or as PorA type = 1.4. RP, relative
otency; PBT, positive bacterial threshold. 95% conﬁdence intervals derived with
he  Clopper–Pearson method.
overed in MATS by only one antigen had seroresponses between
3% and 100%, one ∼60% and one strain only was  below 50%
average 83%). All the 10 strains predicted covered in MATS by
wo antigens had seroresponses >79% (average 93%). In summary,
ATS predicts not only the average susceptibility of meningococ-
al isolates to 4CMenB-induced immunity, but also high levels of
ndividual seroresponse to vaccination.
. Transfer of MATS assay to reference laboratoriesThe distribution of MenB strains and, by corollary, the presence
nd level of expression of vaccine antigens on circulating strains,
aries by geographical area and over time necessitating ongoing
urveillance. As MATS is the only available assay developed to
Fig. 3. Proportion of subjects protected by 4CMenB  (2015) 2629–2636
assess strain coverage for 4CMenB, a harmonized method of assess-
ment is essential for countries considering inclusion of Bexsero on
their routine immunization schedule. Thus, it was  imperative that
MATS be transferred to reliable national reference laboratories.
Although PorA typing to predict coverage by the OMV  com-
ponent is well established, the behavior and repeatability of the
MATS–ELISA in various labs had to be determined to ensure con-
sistency in MATS estimated coverage between labs. Therefore, an
inter-laboratory study was  conducted to conﬁrm the utility of
the MATS methodology and establish standard procedures [32]. A
detailed comparison of MATS–ELISA results from 17 diverse MenB
strains was  conducted in 7 labs in France, Germany, Italy, Norway,
Spain, the United Kingdom, and the United States [32]. Each lab
assessed the same set of MenB strains, which were selected to pro-
vide examples of a range of MATS–ELISA values, not to represent
any particular country or region.
Each lab performed multiple MATS–ELISA tests for fHbp, NadA
and NHBA on each strain and determined RPs for each antigen, as
previously described [28]. The resulting multiple RPs per strain and
antigen were used to estimate consensus RPs across labs for each
strain and antigen. Differences in RPs between labs were found to
be small and had only a minor impact on consensus RPs, indicating
good reproducibility [32]. Differences in RPs within labs were 2–2.5
times greater than between-lab variation for each antigen, which
demonstrates very good assay standardization across labs [32].
Data from this study was  used to compute 95% conﬁdence inter-
vals (CI) for PBTs, making it possible to not only predict, but also to
provide empirical limits of predicted strain coverage by 4CMenB.
MATS RPs produced in any qualiﬁed lab can therefore be compared
to other qualiﬁed laboratories in order to compute robust estimates
of vaccine strain coverage that are consistent among laboratories,
within a 95% CI.
The results of this study show that MATS can be considered
a standardized, reproducible method to predict 4CMenB strain
coverage. To ensure appropriate assessment of the public health
beneﬁt of 4CMenB and in the spirit of public–private coopera-
tion, the vaccine manufacturer has made the MATS assay platform
available to these meningococcal reference laboratories around the
world to facilitate the timely collection and analysis of regional data
to estimate 4CMenB strain coverage in speciﬁc geographical areas.
versus the number of MATS-positive antigens.
D. Medini et al. / Vaccine 33 (2015) 2629–2636 2633
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More than half of all cases of invasive meningococcal disease
in Canada are caused by serogroup B and children under 5 are at
the highest risk. Bettinger and colleagues used MATS to predict
4CMenB coverage against MenB strains isolated in Canada fromFig. 4. Global MATS cov
. Estimated 4CMenB coverage in countries around the
orld
MATS has already been used to estimate strain coverage in a
umber of countries. Fig. 4 shows estimated strain coverage in 13
ountries around the world: Australia, Brazil, Canada, Czech Repub-
ic, England and Wales, France, Germany, Greece, Italy, Norway,
pain, and the United States, with predicted coverage by 4CMenB
anging from 66% (95% CI, 43–78%) to 91% (95% CI, 72–96%) [33–40].
Vogel and colleagues assessed all MenB isolates from 5 Euro-
ean countries that had been submitted to reference laboratories
ver a full epidemiological year from July 2007 to June 2008 [37].
verall, 1052 MenB strains were collected in England and Wales
n = 535), France (n = 200), Germany (n = 222), Italy (n = 54), and
orway (n = 41). All strains contained at least one gene encoding a
ajor antigen in 4CMenB. The predicted 4CMenB coverage in indi-
idual countries ranged from 73% (95% CI, 57–87%) in England and
ales to 87% (95% CI, 70–93%) in Italy. Overall, MATS predicted
hat 78% of all MenB strains would be killed by post-vaccination
era (95% CI 63–90%). Importantly, 50% of all strains and 64% of
overed strains could be targeted by antibodies against more than
ne 4CMenB antigen ensuring redundancy to help reduce the risk of
he emergence of variants not covered by the vaccine (Fig. 5A). The
ajor clonal complexes and PorA subtypes of endemic European
enB strains were assessed and clonal complexes 32, 41/44, and
69 were shown to account for most strains. Although the propor-
ions varied between countries, the overall distributions of the most
ommonly isolated clonal complexes were similar (Fig. 5B) [37].
To investigate whether the predicted coverage in these 5 Euro-
ean countries could be generalized to the rest of Europe, Vogel
nd colleagues assessed isolates from the Czech Republic (n = 108)
nd Spain (n = 300), where respective coverage rates of 74% (95%
I, 58–87%) and 69% (95% CI, 48–85%) were predicted [37]. These
esults were consistent with those for the other 5 European coun-
ries (overall estimated coverage 78%, 95% CI 63–90%), suggesting
hat estimated coverage for the 5 European countries was robust
nd representative for other European countries [37]. estimates for 4CMenB.Fig. 5. (A) Percentage of invasive MenB strains MATS-positive by number of anti-
gens > PBT, per country and overall. (B) Distribution of clonal complexes in the panel
of  1052 strains, by country and overall.
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006 to 2009 [35]. Overall, 157 isolates were tested and the MATS
redicted strain coverage was 66% (95% CI, 46–78%), which is also
omparable to rates found by Vogel and colleagues in Europe [37].
mportantly, predicted coverage was very high for the two most
revalent recent strains in Canada [sequence type (ST)-269, 95%;
T-154, 100%].
In Australia, 373 MenB isolates collected from 2007 to 2011 were
nalyzed to estimate 4CMenB coverage in Australia [33]. Overall,
ATS-estimated coverage was 76% (95% CI, 63–87%) and 37% of
trains were covered by more than one 4CMenB antigen.
Isolates from Brazil (n = 99; 2010), Greece (n = 148; 2008–2010),
nd the United States (n = 442; collected in 2000–2008) were also
ssessed to estimate 4CMenB coverage rates in these countries
34,38–40]. Rates of 81% (95% CI, 71–95%), 89% (64–99%), 88% (95%
I, 60–96%), and 91% (95% CI, 72–96%) were found in Brazil, Greece,
nd the United States, respectively [34,38–40].
In 2013, there were two  outbreaks of meningococcal serogroup
 disease at US universities – at Princeton University and the Uni-
ersity of California Santa Barbara. Isolates from these outbreaks
ere tested by the CDC and GSK laboratories and were predicted
s covered by 4CMenB. The CDC and FDA implemented a program
nder an expanded access Investigational New Drug (IND) Proto-
ol, over 14,000 students have received 4CMenB and subsequently,
CMenB received Breakthrough status by the US FDA [20,41–43].
CMenB was approved for use in individuals from 10 to 25 years of
ge by the FDA in January of 2015 [21].
The components of 4CMenB are also present in some invasive
on-B serogroup isolates, which suggests the potential protection
f 4CMenB against non-B serogroups. It should be noted that the
ATS PBTs for fHbp, NHBA and NadA were derived on serogroup
 strains and their use to predict non-B strain coverage has not
et been validated. In a study designed to estimate 4CMenB cover-
ge in Australia, 108 meningococcal non-B isolates (serogroups C
n = 50], W [n = 27], Y [n = 30] and X [n = 1]) were also tested using
ATS [33]. Of the non-B strains tested, 56% (39–76%) exceeded PBTs
or at least 1 4CMenB antigen [C, 64% (46–86%); W,  63% (41–93%);
, 37% (27–43%)] [33]. These preliminary results using MATS with
on-B strains indicate that non-B strains circulating in Australia
xpress signiﬁcant levels of 4CMenB antigens. In a study conducted
n Brazil, a representative subpanel of 4 MenC, 7 MenW and 9 MenY
trains was tested in hSBA and in immune serum pools from ado-
escents and infants who had received 4CMenB. In adolescents, the
roportion of strains killed at hSBA titers ≥1:8 was 100% for MenC,
6% for MenW,  and 67% for MenY. In infants, the MenC strains were
ot killed, but 100% of MenW and MenY strains were killed [34,40].
eningococcal serogroup X (MenX) has emerged in the African
eningitis belt and there is currently no capsule-based vaccine
gainst MenX. A study was conducted using MATS to investigate
he levels of expression of 4CMenB antigens in 11 MenX isolates
rom several African countries (Burkina Faso, Chad, Niger; n = 9)
nd France (n = 2) [44]. The MenX isolates from Africa were of the
ame genotype but differed from the isolates from France. SBA
ssays were performed using pooled sera from 4CMenB-vaccinated
nfants, adolescents and adults. MATS data and SBA assays sug-
ested 4CMenB coverage of the 9 African MenX isolates but not
he 2 MenX isolates from France. Further investigation is required
o determine whether 4CMenB could be used against MenX and
ther non-B serogroups. PBTs for fHbp, NHBA and NadA would need
o be validated for non-B strains in order to reliably use MATS to
stimate 4CMenB coverage for non-B strains.. MATS is a conservative predictor of 4CMenB coverage
MATS is considered conservative, underestimating coverage
articular in older age groups. The choice to apply PBTs derivedFig. 6. 4CMenB strain coverage in England & Wales predicted by MATS, and mea-
sured by hSBA.
on infant sera to all age groups was  intentionally made to avoid
overestimation of coverage. A consequence of that choice was  some
level of underestimation, as demonstrated by the observation that
strains that were killed in hSBA were not always predicted to be
killed by MATS, particularly in older ages (63% in adults [28]). MATS
may  also underestimate 4CMenB coverage due to the contribu-
tion of additional antigens in OMV  (e.g. PorB, Opc, FetA and Los)
for which typing was  not performed [28]. Furthermore, potential
synergistic effects of the multiple components of 4CMenB are not
accounted for in the MATS estimate [28,45,46]. For example, anti-
bodies that are not bactericidal individually have been observed to
augment bactericidal antibodies against NHBA in the SBA [17,28].
In addition, NadA expression is repressed under in vitro growth
conditions used in both MATS and hSBA [47] and NHBA expression
is temperature-regulated and is reduced at 37 ◦C, the temperature
at which MATS is performed [48].
In order to determine the accuracy of MATS-based predictions
in a given geographical area and epidemiologic time span, MATS
predictions would need to be compared to hSBA, the correlate
of protection. The accuracy of MATS-predicted coverage against
strains in a speciﬁc epidemiological setting was  experimentally
assessed in a study by Frosi and colleagues [49]. A stratiﬁed pro-
portional sampling procedure was  used to identify a non-biased
and representative 40-strain panel out of the 535 MenB isolates
that had been collected in England and Wales from July 2007
to June 2008 [37]. These strains were tested in hSBA in order
to compare the correlate of protection results with MATS pre-
dicted coverage. As previously, killing in hSBA was deﬁned as a
post-vaccination hSBA titer ≥1:8 and ≥4-times higher than the cor-
responding pre-vaccination titer (hSBA+) while MATS-predicted
coverage was deﬁned as RP > PBT for NadA, NHBA or fHbp, or if
PorA type = 1.4 (MATS+).
There was a signiﬁcant association between the MATS and hSBA
results (p = 0.022). As can be seen in Fig. 6A, 88% (95% CI, 72–95%) of
strains in both age groups were hSBA+ while 70% (95% CI, 55–85%)
were MATS+. Fig. 6B illustrates the high level of agreement between
MATS and hSBA results, with 27 true-positives (MATS+, hSBA+) and
4 true-negatives (MATS−,  hSBA−). In the few cases of disagree-
ment between MATS and hSBA, MATS tended to be conservative,
as demonstrated by only 1 strain predicted as covered but not killed
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n hSBA (MATS+, hSBA−) and 8 strains predicted as not covered that
ere killed in hSBA (MATS−,  hSBA+). As a predictor of hSBA, MATS
ad a 96% positive predictive value and an overall accuracy of 78%.
he results of this study showed that MATS provides an accurate
nd conservative prediction of 4CMenB strain coverage.
. MATS as a tool for post-implementation surveillance
Post-implementation programs for meningococcal vaccines are
esigned to obtain information regarding safety and effectiveness
nd to assess the ability of the vaccine to continue to help prevent
MD  in the target population [50]. Post-implementation surveil-
ance will be crucial to continue to evaluate the effectiveness and
overage of 4CMenB over time. A detailed review of the challenges
f post-implementation surveillance for novel meningococcal vac-
ines has been published [50].
MATS is a useful tool for ongoing post-licensure surveillance
f the effectiveness of 4CMenB. The established reference labs can
se MATS to obtain information regarding bacterial strain cover-
ge before and after introduction of 4CMenB. MATS can also be
sed to detect epidemiological trends and to determine the effect
f 4CMenB on the distribution and carriage of bacterial strains in
 deﬁned geography. Within the context of efﬁcacy surveillance,
nd paired with genotypic characterization, MATS can provide
n on-going snapshot of the 4CMenB impact on meningococcal
opulations, and predict changes in the vaccine efﬁcacy before
hey occur. Because the antigens in 4CMenB also occur in other
erogroups, MATS could be used to assess the impact of 4CMenB on
eningococcal disease caused by strains of other serogroups [50].
n addition, MATS can be used to screen for the possible emergence
f variants resistant to vaccine-induced immune responses.
In the future, MATS could be used to describe the nature of
otential vaccine failures or breakthrough cases, i.e., cases of MenB
hat occur in vaccinated subjects with strains predicted to be killed
y MATS [32]. These data can also be used to demonstrate dura-
ion of protection afforded by vaccination and inform subsequent
evelopment of vaccine booster schedules, if necessary. Data from
ost-implementation surveillance based on a standardized assay
uch as MATS may  allow indirect comparison of immunization poli-
ies across countries and regions and allow rapid adaptation of
ublic health policy decisions to be based on worldwide datasets
32].
. Conclusion
MATS is a standardized, reproducible antigen typing system that
llows not only prediction of 4CMenB coverage but also empirical
ntervals of predicted strain coverage by 4CMenB. It is an accu-
ate, though conservative estimate that can be performed in any of
he standardized reference laboratories around the world to assess
CMenB coverage in speciﬁc geographical regions. Global estimates
f 4CMenB strain coverage ranged from 66% to 91%, per country.
ATS will be used in post-implementation surveillance to monitor
he effectiveness and coverage of 4CMenB over time.
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